Arrowhead Listing Upgraded to NASDAQ Global Select Market

PASADENA, Calif.--()--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received notice that the NASDAQ Listing Qualifications Department has approved an application to upgrade the listing of the Company’s securities from the NASDAQ Capital Market to the NASDAQ Global Select Market, effective with the opening of business on February 21, 2014. The NASDAQ Global Select Market is the segment for public companies that meet the highest listing standards of NASDAQ, with requirements that include market value, financial, and liquidity measurements. The Company’s stock will continue to trade under the ticker symbol “ARWR” after the upgrade.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to ir@arrowres.com.

Contacts

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
The Trout Group
Lauren Glaser
646-378-2972
ir@arrowres.com

Release Summary

Arrowhead Listing Upgraded to NASDAQ Global Select Market

Sharing

Contacts

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
The Trout Group
Lauren Glaser
646-378-2972
ir@arrowres.com